An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes x-rays that track the body from the outside. CT images provide an exact outline of the organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. Metabolic information means how much of the injected tracer is taken up by inflammatory tissue. Flotufolastat F 18 PET/CT imaging may be an effective and less invasive way to detect residual or recurrent disease in prostate cancer patients, compared to other methods.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku od 18 do 90 lat.
- •Historia raka prostaty.
- •Przeszli leczenie miejscowe raka prostaty (np. laserem, krioterapią) w ciągu ostatnich 6-36 miesięcy.
✗ Disqualifies
- •Nie mogą mieć wykonanego specjalnego skanu PET/CT.
- •Nie mogą mieć wykonanej biopsji prostaty pod kontrolą USG.
- •Nie mogą mieć podanego środka kontrastowego lub innego znacznika promieniotwórczego mniej niż 24 godziny przed badaniem PET.
- •Nie mogą mieć niskiego poziomu testosteronu z powodu terapii hormonalnej.
- •Nie mogą mieć lęku przed ciasnymi przestrzeniami (klaustrofobii) lub nie mogąc leżeć nieruchomo podczas skanu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 90 Years
- Last updated (source)
- September 29, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, United States
Trial contact
Kyla Grunden
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/30/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.